

CURRICULUM VITAE

J. DAVID PORT, Ph.D.

Business Address: University of Colorado HSC
Departments of Medicine and Pharmacology
Division of Cardiology
Campus Box B139
Denver, CO 80262
Tel: 303-315-3260
FAX: 303-315-3262 or 3261
e-mail: david.port@uchsc.edu

EDUCATION

- 1991 Post-doctoral Fellowship, SUNY Stony Brook, Stony Brook, NY
- 1989 Ph.D. in Pharmacology, University of Utah, Salt Lake City, UT
- 1979 B.S. in Biology, University of Utah, Salt Lake City, UT

PROFESSIONAL EXPERIENCE

- 2005 Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO
- 1998- Associate Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO;
Member, MSTP Training Faculty (1999)
Tenure (2001)
- 1991-1998 Assistant Professor, Departments of Medicine and Pharmacology, Division of Cardiology, University of Colorado, School of Medicine, Denver, CO
- 1979-1985 Technical Director of Research, Department of Anesthesiology, University of Utah, School of Medicine, Salt Lake City, UT

AWARDS AND HONORS

University of Colorado Health Sciences Center, Department of Medicine “Ph.D. Research and Teaching Award”, 1998

University of Colorado Health Sciences Center, Department of Pharmacology “Teaching Award”, 2001

FINANCIAL SUPPORT, MAJOR GRANTS

NIH Pre-Doctoral Fellowship, 1985-1988
University of Utah
Department of Pharmacology

American Heart Association, New York State Affiliate,
Post-Doctoral Fellowship
\$60,000 over 2 years (1990/91)
Project Title: Transmembrane signaling in idiopathic dilated cardiomyopathy: Models for study of G-protein biology.

Long Island Heart Association
Co-investigator, C.C. Malbon, Principal Investigator
Supplement to AHA Fellowship (1990-1991), \$30,000 over 2 years (supplies)
Project Title: Transmembrane signaling in idiopathic dilated cardiomyopathy: Models for study of G-protein biology.

Sepracor, Inc.
Co-investigator, M.R. Bristow, Principal Investigator
Contract: \$20,000 (1992)
Project Title: Effect of racemic and enantiomeric forms of atenolol and metoprolol on β -adrenergic receptor density in primary cultures of chick cardiomyocytes.

Boehringer Mannheim GmbH
Co-investigator, M.R. Bristow, Principal Investigator
Contract: \$160,000 over 2 years (1992-3)
Project Title: Further studies on the mechanism of action of carvedilol in human adrenergic receptor systems.

Colorado Heart Association
Principal Investigator
Beginning Grant-In-Aid
\$22,000 for 1 year (7/93 to 6/94)
Project Title: Regulation of beta-adrenergic receptor mRNA stability.

NIH
Principal Investigator
RO1 HL51239-06A1
\$350,000 (1-94 to 11-99)
Project Title: Regulation of beta-adrenergic receptor mRNA stability.
Colorado Heart Association

Principal Investigator
Beginning Grant-In-Aid
\$25,000 for 1 year (7/95 to 6/96)
Project Title: Regulation of human beta1-adrenergic receptor by phosphorylation.

University of Colorado Cancer Center
Principal Investigator
Research Project
\$13,500 for one year (9/96 to 8/97)
Project Title: Nucleotide binding specificity of mRNA protein, AUF1

Colorado Heart Association
Principal Investigator
Standard Grant-In-Aid
\$60,000 over 2 years (7/97 to 6/99)
Project Title: Role of AUF1 in the regulation of beta-adrenergic receptor mRNA stability.

Astra-Merck
Principal Investigator
Research Grant
\$49,740 over 1 year (1/98 to 12/98)
Project Title: Post-transcriptional regulation of β -adrenergic receptor genes.

NIH
1 S10 RR13955-01
Co-Investigator: J. Weil, Principal Investigator
Common Equipment Grant
\$287,700 over 1 year (4/99 to 3/00)
Project Title: Small animal echocardiography system.

American Heart Association, Desert/Mountain Affiliate
Standard Grant-In-Aid
Principal Investigator
\$79,928 over 2 years (7/99 to 6/01)
Title: Overexpression of the human beta1-adrenergic receptor in transgenic mice.

NIH
RO1 HL51239
Principal Investigator
\$778,847 (9/30/99-9/30/04)
Title: Regulation of beta-adrenergic receptor mRNA stability.

AstraZeneca Principal Investigator
Research Grant
\$75,000 (04/01 to 03/02)
Project Title: Effects of beta-blockade on the progression of heart failure in transgenic mice over-expressing the human beta1-adrenergic receptor.

RO1 HL048013
(M.R. Bristow, P.I.; J.D. Port, investigator) 12/03-11/07

10%

NIH 1,906,205 (direct costs) to P.I.
Project Title: Genetic-adrenergic interactions in myocardial failure

NIH
RO1 HL51239
Principal Investigator (07/01/04-6/31/09) 50%
\$1,250,000 (direct costs)
Title: Regulation of beta-adrenergic receptor mRNA stability.

T32 (Boris Tabakoff, P.I., J.D. Port, co-P.I) 07/04-06/09 10% (no salary)
NIH 1,459,912 (direct costs) to P.I.
Title: Predoctoral training program in pharmacology

NIH
RO1 AG15897
Douglas Seals, P.I., J.D. Port, co-P.I.) (12/01/04 – 11/30/09) 10%
\$250,000 (direct costs to P.I.)
Title: Human aging and beta-adrenergic receptor modulation in thermogenesis.

University of Colorado Technology Transfer Office
PoPg Grant
Principal Investigator (12/01/07 – 05/01/08)
\$24,925 (direct costs to PI)
Title: microRNAs as therapeutic targets in heart failure

FINANCIAL SUPPORT, MINOR GRANTS AND TRAINEE SUPPORT

University of Colorado
Mentor
UROP award to Neil Harris
\$750.00 for Summer research project (1995)
Project Title: Regulation of β 1-AR mRNA

American Heart Association
Recipient, New Investigator Award (1996)
\$750 for travel to AHA Scientific Conference of the Molecular Biology of the Normal,
Hypertrophied, and Failing Heart

University of Colorado
Mentor
Howard Hughes SURF award to Neil Harris
\$2000 for Summer research project (1996)
Project Title: Translational effects on destabilization of human β 1-AR mRNA

Merck, Inc.
Recipient
Educational Grant to Department of Pharmacology
\$1000 (1997)

Astra-Merck, Inc.

Recipient
Educational Grant to Division of Cardiology
\$1000 (1997)
PhRMA Foundation
Mentor
Advanced Predoctoral Fellowship
Awarded to Burns C. Blaxall (graduate student, Dept. of Pharmacology)
\$25,000 for two years (4/97 to 3/99)

AstraZeneca, Inc.
Recipient
Educational Grant to Department of Pharmacology
\$5000 (1999)

FINANCIAL SUPPORT (PENDING)

NIH
PPG
Overall PI, Leslie Leinwand
Project Leader (submitted 01/09) 50%
\$1,250,000 (direct costs)
Title: Post-transcriptional gene regulation in heart failure

NIH
RO1 HL51239
Principal Investigator (12/01/00-11/30/14) 50%
\$1,250,000 (direct costs)
Title: Regulation of beta-adrenergic receptor mRNA stability.

PATENTS

1998 U.S. Patent # 5,733,728. JD Port and G Brewer, "Detecting and treating heart failure".
2001 U.S. Patent # 6,218,597. JD Port and MR Bristow, "Transgenic Model and Treatment for Heart Disease".
2001 U.S. Patent #6,203,776. MR Bristow and JD Port, "Method for Identifying Adrenergic Receptor Antagonists Having Good Tolerability".
2002 US Patent #6,436,636 B1. JD Port and G. Brewer. "Methods for identifying pharmacologicals for the treatment of heart failure".
2007 miRNAs as diagnostic and therapeutic targets in heart failure. (submitted)
2008 U.S. Provisional Patent Application #61/085,586 "Methods and composition involving (S)-bucindolol"

COMMERCIAL EXPERIENCE

2005 Scientific co-founder and CTO, ARCA Discovery
2006- VP Research & Technology, ARCA Discovery
2007 Scientific co-founder, MiRagen

TEACHING

University of Utah Health Sciences Center:

Pharm 572. Cardiac glycosides and other positive inotropic agents in congestive heart failure. (lecture to third year pharmacy students) 1988 and 1989

Pharm 604. Cardiac glycosides and other drugs for congestive heart failure. (lecture to second year medical students) 1988 and 1989

University of Colorado Health Sciences Center:

Pharm 7620. Research topics. (lecture to first year pharmacology graduate students) 1992, 96, 97

Pharm 6000. Medical Pharmacology. (lecture to second year medical students)
Cardiac glycosides and other drugs for congestive heart failure (2 hrs/year), 1993, 94, 95, 96, 97, 98, 99, 00, 01, 02, 03, 04, 05, 06
Treatment of angina (2 hrs/year), 1995, 96, 97, 98, 99, 00, 01, 02, 03, 04, 05, 06
Course reviewer/monitor for other lectures on cardiovascular topics, 1996, 97, 98, 99, 00, 01

Pharm 7620 Principles of Pharmacology (Graduate Pharmacology)
Cardiovascular Pharmacology, section organizer
lecture to first and second year graduate students on G-protein coupled receptor signaling and on cardiac-related topics, 6-8 lecture hours/year 1999, 00, 01, 02, 03, 04, 05, 06, 07, 08, 09

Integrated Curriculum, First Year Medical Students
Treatment of Congestive Heart Failure, 2 hrs/year. 2006, 07, 08, 09
Treatment of Angina, 1 hr/year. 2006, 07, 08, 09

IDPT 7646 Tissue Biology and Disease Mechanisms
Lecture to graduate students on heart failure related topics. 2006

Pharm 7600 Frontiers in Pharmacology. Course Director and lecturer 1998. Literature-based directed reading/lecture course covering contemporary topics in pharmacology. lecture, 1999, 00, 01

Basic Science 6600 Dental Pharmacology. Course reviewer/monitor for lectures on cardiovascular topics, 1994, 95, 96, 97, 98, 99, 00

Pharm 7617 Molecular Pharmacology.
lecture to second year pharmacology grad students 1994, 95, 96, 97, 98

Path 6000 Alternative Pathology (lecture to MSTP and graduate students on the molecular basis of heart failure), 1994, 95, 96, 97, 98, 99, 00

Pharm 7605 Ethics in Research. Co-course Director, 1999; small group discussion leader, 99, 00, 01

Division of Cardiology: (lecture to cardiology fellows on basic pharmacological principles) 1996

PEER REVIEW

Journals

Ad Hoc reviewer, American Journal of Cardiology
Ad Hoc reviewer, American Journal of Physiology
Ad Hoc reviewer, Anatomical Record
Ad Hoc reviewer, Atherosclerosis
Ad Hoc reviewer, Biochemical Pharmacology
Ad Hoc, reviewer, Biochimica et Biophysica Acta
Ad Hoc reviewer, Cardiovascular Research
Ad Hoc reviewer, Circulation
Ad Hoc reviewer, Circulation Research
Ad Hoc reviewer, European Journal of Pharmacology
Ad Hoc reviewer, Experimental Cell Research
Ad Hoc reviewer, FASEB J
Ad Hoc reviewer, Heart and Vessels
Ad Hoc reviewer, Hypertension
Ad Hoc reviewer, Journal of the American College of Cardiology
Ad Hoc reviewer, Journal of the American Medical Association (JAMA)
Ad Hoc reviewer, Journal of Applied Physiology
Ad Hoc reviewer, Journal of Biological Chemistry
Ad Hoc reviewer, Journal of Cardiovascular Pharmacology
Ad Hoc reviewer, Journal of Cardiac Failure
Ad Hoc reviewer, Journal of Clinical Investigation
Ad Hoc reviewer, Journal of Molecular Biology
Ad Hoc reviewer, Journal of Molecular and Cellular Cardiology
Ad Hoc reviewer, Journal of Molecular Medicine
Ad Hoc reviewer, Journal of Pharmacology and Experimental Therapeutics
Ad Hoc reviewer, Life Science
Ad Hoc reviewer, Molecular and Cellular Biochemistry
Ad Hoc reviewer, Molecular and Cellular Biology
Ad Hoc reviewer, Molecular Pharmacology
Ad Hoc reviewer, Proc. Natl. Acad. Sci. U.S.A.
Ad Hoc reviewer, Science

Grant Review

Institutional

1996 University of Colorado, Health Sciences Center/School of Engineering
Biomedical seed grant review committee

National/Regional

1994 Member, American Heart Association, Western Consortium Peer Review
Committee
1995,96,97 Member, American Heart Association, Affiliate Study Group G (Molecular
Signaling) Committee
1998 **Co-Chair**, American Heart Association, Colorado/Wyoming Affiliate Peer
Review Committee
1999, 2000 **Chair**, American Heart Association, Great America Affiliate Molecular
Signaling (5E) Peer Review Committee

2001 Member, American Heart Association, Great America Affiliate Molecular Signaling (5E) Peer Review Committee

2002-03 **Co-Chair**, American Heart Association, Molecular Signaling II National Study Section

2002-03 Member (temporary), Pharmacology Study Section, NIH

2003-04 NIH, NHLBI, Program Project Grant reviewer (3 occasions)

2003 Member, Pharmacology Study Section, NIH

2004-07 Member, Vascular Cell and Molecular Biology Study Section, NIH

2007 Member (ad hoc), Training Grant review Study Section, NIH

2009 Member (ad hoc), Molecular Genetics "B" Study Section, NIH

2009 NIH, NHLBI, Program Project Grant reviewer

PROFESSIONAL MEMBERSHIPS

American Association for the Advancement of Science

American Society for Microbiology

American Society of Cell Biology (inactive)

American Heart Association, Basic Science Council

American Society of Biochemistry and Molecular Biology (inactive)

American Society of Pharmacology and Experimental Therapeutics, Division of Molecular Pharmacology (**Member, Program Committee 1998 -2006**)

Heart Failure Society of America (**Member, Program Committee 2000-2002**)

RNA Society

TRAINING

1993-94 John Sherman, B.S. summer student (currently in Cardiology Fellowship at Dartmouth)

1994-96 Aldo Pende, M.D., postdoctoral fellow (currently on faculty at the University of Genoa, IT)

1994-96 Neil Harris summer student (completed M.D. training)

1994-99 Burns Blaxall, Ph.D. graduate student, Dept. of Pharmacology (currently on faculty at University of Rochester)

1995-97 John Bisognano, M.D., Ph.D. Bugher Post-doctoral Fellow, Cardiology (currently on faculty at the University of Rochester)

1998-99 Amornrate Sastravaha, D.V.M. research position in Thailand

2001 Scott Greene summer student, NCI research fellowship (currently in medical school)

2001 Pippa Cospers summer student, NCI research fellowship (currently in MD/PhD program)

2001 Carrie Eckert graduate student, Biomedical Sciences Program

2001 Laura Zerbe, Ph.D. co-mentor, post-doctoral fellowship

2002-04 Kathy Gleason, Ph.D. postdoctoral fellow

2004 Brad Engel summer student

2004 Leslie Adams summer student

2005 Avery Berg summer student

2005- Pamela David Gerecht, Ph.D. postdoctoral fellow

2007 Molly Ann Taylor graduate student, Biomedical Sciences Program

2007 Nicole Vitesse summer student, NCI research fellowship

2007 Kelsey Flint medical student, research mentor program

2008 Mary Zeng summer student, NCI research fellowship

THESIS & COMPREHENSIVE EXAM COMMITTEES

1993-95	Ron Klein	thesis committee; chair, thesis defense committee
1996	Danny T. Muskardin	thesis committee; chair, thesis defense committee
1994	Mark Wade	comprehensive exam committee
1997	Mark Wade	thesis committee; chair, thesis defense committee
1996	Sue Cibulsky	chair, comprehensive exam committee
1996	Michael Inman	comprehensive exam, thesis committee (Biochem)
1997	Elizabeth Gonzalez	comprehensive exam committee
1998/9	Eric Bush	thesis committee (Cell, Structural Biology)
1999/00	Kalev Freeman	thesis committee (MCDB, UC Boulder)
1999/01	Korinne (Meyer) Jew	thesis committee (Kinesiology, UC Boulder)
2001	Jason Prescott	comprehensive exam, thesis committee (Mol Biol)
2003	Steven Rosinski	thesis committee (Pharmacology)
2005/09	Todd Gangelhoff	comp exam, thesis committee (Mol Biol)
2006	Douglas Donham	comp exam, thesis committee (Pharmacology)
2007/09	Kelli Kline	comp exam, thesis committee (Pharmacology)

COMMITTEES

University of Colorado Health Sciences Center

1997-00	Judge, Annual Graduate Student Research Forum
1997	Recruitment and Admissions Committee, Consolidated Basic Sciences Graduate Program
1997-	Steering Committee, Consolidated Basic Sciences Graduate Program
1998-	UCHSC Graduate Council
1998-	SOM Graduate School Executive Committee
1998-	SOM Graduate School Executive Committee, Bylaws Subcommittee
2000	UCHSC Graduate School, Graduate School Rules Subcommittee
2001	UCHSC Graduate School Financial Resources Committee
2001-	UCHSC Fiscal Planning Committee
2003	Steering Committee, Medical Scientist Training Program (MSTP)
2003-	UCHSC Faculty Assembly
2006-7	Chancellor's Committee on restructuring of UCDHSC graduate schools
2007-	Core course curriculum oversight committee
2008	Chancellor's Committee on restructuring of UCD Faculty Assemblies

Department of Pharmacology

1997-present	Chair, Graduate Training Committee Co-Director, Graduate Training Program
1993-97	Graduate Training Committee
1994-97	Chair , Seminar Committee
1994	Committee: Role of Joint Appointments in the Department of Pharmacology
2001-	Graduate Student Recruitment/Admissions Committee, <i>ex officio</i>
2001-04	Curriculum Committee
2002	Department of Pharmacology Self-Study Committee

Department of Medicine/Division of Cardiology

1993-95 Role of Ph.D.'s in the Department of Medicine
1995 Research Directives Committee
1995-97 Core Curriculum Committee
1995-96 **Chair**, Seminar Committee
2004-06 Division of Cardiology, Executive Committee
2007-09 Co-chair, Research Seminar Committee
2009 Division of Cardiology Education Committee

External

1997 Member, American Heart Association, Colorado/Wyoming Affiliate Research Committee
1998-01 Member (at large), Program Committee, American Society for Pharmacology and Experimental Therapeutics
1999-00 Member (ad hoc), Program Committee, Heart Failure Society of America
2000-02 Member, Program Committee, Heart Failure Society of America
2001-04 FASEB Summer Research Conferences Advisory Committee, ASPET representative
2001-present Member (at large), ASPET, Division of Molecular Pharmacology, Executive Committee
2001-02 Research Committee, Desert Mountain Affiliate of the American Heart Association
2001-06 Representative to Program Committee, Division of Molecular Pharmacology, American Society of Pharmacology and Experimental Therapeutics
2003 Member, AHA Committee on implementation of grant review triage process
2003-05 **Chair**, Research Committee, Pacific Mountain Affiliate of the AHA
2003-05 Member, Board of Directors, Pacific Mountain Affiliate of the AHA
2003-05 **Co-Chair**, National AHA Peer Review Steering Committee
2005-07 Member, Strategic Planning Committee, Pacific Mountain Affiliate of the AHA
2005-07 **Chair**, National AHA Peer Review Steering Committee
2006-07 President Elect, Board of Directors, Pacific Mountain Affiliate of the AHA
2007-08 **President**, Board of Directors, Pacific Mountain Affiliate of the AHA
2008-09 Past President, Board of Directors, Pacific Mountain Affiliate of the AHA
2009 President Elect, Board of Directors, Denver Metro Board of the AHA
2009 President Elect, ASPET, Division of Molecular Pharmacology

OTHER SERVICE

1998 Session Moderator, Human Heart Failure: Molecular Mechanisms, AHA National Meeting
1998 Session Moderator, Biochemical Abnormalities in Failing Human Heart, AHA National Meeting
1999 Program Organizer/Chair, Short Course on "Surfing the Genome", ASPET/Experimental Biology 99
1999 Session Moderator, Altered Intracellular Signal Transduction in Hypertrophy and Failure, Heart Failure Society of America National Meeting
2000 Session Moderator, G-proteins and Kinase Cascade Signaling Pathways, Heart Failure Society of America National Meeting

- 2000 Session Moderator, Workshop on “Mining the (Genomic) Data Bases”, Heart Failure Society of America National Meeting
- 2000 Session Moderator, Polymorphisms in Patients with Heart Failure, AHA National Meeting
- 2001 Abstract Grader, Heart Failure Society of America National Meeting
- 2001 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2001 Session Moderator, Adrenergic Mechanisms in Heart Failure, Heart Failure Society of America National Meeting
- 2002 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2002 Session Moderator, Genomics and Genetics, Part II, Heart Failure Society of America National Meeting
- 2003 Symposium Organizer/Chair, Transgenic Mouse Models of Heart Failure and Heart Failure Therapeutics, ASPET/Experimental Biology 03
- 2003 Meeting Co-organizer, First International Meeting on AREs and AUBPs in Translational Control, Florence, Italy
- 2003 Session Moderator, Late Breaking Science, Heart Failure Society of America National Meeting
- 2004 Symposium Organizer/Chair, Polymorphisms in signaling cascades and effector molecules, ASPET/Experimental Biology 04
- 2005 Session Moderator, Biological and therapeutic application of RNAi, Heart Failure Society of America National Meeting
- 2007 Symposium Organizer/Chair/Speaker, Post-transcriptional regulation of gene expression, ASPET/Experimental Biology 07
- 2008 Young Investigator Selection Committee, Heart Failure Society of America National Meeting
- 2008 Meeting Organizer, Invited Speaker, RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, Asheville, NC, 2008
- 2009 Symposium Organizer/Chair/Speaker, microRNAs as biological effectors and pharmacological targets in the cardiovascular system, ASPET/Experimental Biology 09
- 2009 Symposium Chair, microRNAs, Heart Failure Society of America National Meeting

BIBLIOGRAPHY

Ph.D. Dissertation:

Port JD. I. Lack of spare β -adrenergic receptors in human ventricular myocardium. II. Pharmacological characterization of chick and frog myocardial β -adrenergic receptors. 1989

Book Chapters:

1. Bristow MR, **Port JD**: Receptor Pharmacology of the Human Heart. in, Current Concepts in Cardiovascular Physiology. O.B. Garfein ed., Academic Press. pp. 73-132, 1990.
2. **Port JD**, Pende A, Valent S, Bristow MR. Adrenergic Receptors: Relevance to Myocardial Signal Transduction in Heart Failure. L. Dei Cas and C. V. Leier, eds. UTET Periodici Scientifici srl. pp 8-19, 1995
3. Abraham WT, **Port JD**, Bristow MR. Neurohormonal Receptors in the Failing Heart. In: Heart Failure. Poole-Wilson PA, Chatterjee K, Coats AJS, Colucci WS, Massie B. eds. New York, Churchill Livingstone pp 127-141, 1997

4. Blaxall BC, **Port JD**. Binding of adrenergic receptor mRNA to cellular proteins: use of UV cross-linking and other methods for identification and determination of size and affinity. In: *Methods in Molecular Biology. Adrenergic Receptor Protocols*. Curtis Machida, editor. Humana Press, Inc. vol. 136, pp. 453-465, 2000
5. Bristow MR, **Port JD**, Kelley R, Chapter 18. Drugs Used to Treat Heart Failure. In: *Heart Disease. A Textbook of Cardiovascular Medicine*. 6th Edition. Braunwald E, Zipes D, and Libby P. eds. W.B. Saunders Co., pp. 562-599, 2001
6. Bristow MR, **Port JD**, Kelley R, Pharmacologic Management of Congestive Heart Failure. In: *Cardiovascular Therapeutics 2nd Edition: A Companion to Braunwald's Heart Disease*. Antman, E.M., ed. W.B. Saunders Co., pp300-324, 2002
7. **Port JD**, Linseman J, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: *Heart Failure: A Companion to Braunwald's Heart Disease*. Mann, D.L., ed. W.B. Saunders Co., pp 145-158, 2004
8. Bristow MR, Linas S, and **Port JD**, Drugs in the Treatment of Heart Failure. In: *Heart Disease. A Textbook of Cardiovascular Medicine*. 7th Edition. Braunwald E, Zipes D, and Libby P. eds. Ch 23, pp 569-601, 2005
9. **Port JD**, and Bristow MR. Adrenergic Receptor Coupling and Uncoupling in Heart Failure In: *Molecular Mechanisms for Cardiac Hypertrophy and Failure* Richard A. Walsh, M.D., Editor, Ch 20 pp 323-340, 2005
10. **Port JD**, Sucharov, and Bristow MR, Adrenergic Receptor Signaling in Chronic Heart Failure. In: *Heart Failure: A Companion to Braunwald's Heart Disease*. Mann, D.L., ed. W.B. Saunders Co.(in process), 2009

Manuscripts:

1. Reddy P, Liu WS, **Port JD**, Gillmor S, Stanley TH: Comparison of hemodynamic effects of anesthetic doses of alphaprodine and sufentanil in the dog. *Canad Anaesth Soc J* 27:345-350, 1980
2. Sederberg J, Stanley TH, Reddy P, Liu WS, **Port JD**, Gillmor ST: Hemodynamic effects of butorphanol-oxygen anesthesia in dogs. *Anesth Analg* 60:715-719, 1981
3. Liu WS, Wong KC, **Port JD**, Andriano K: Epinephrine induced arrhythmias during halothane anesthesia with the addition of nitrous oxide, nitrogen, and helium in dogs. *Anesth Analg* 61:414-417, 1982
4. Meuleman TR, Hill DC, **Port JD**, Stanley TH, Pace NL, Mohammad SF: Ketanserin prevents platelet aggregation and endotoxic-induced pulmonary vasoconstriction. *Crit Care Med* 11:606-611, 1983
5. Wong KC, **Port JD**, Steffens JG: Cardiovascular responses to asphyxial challenge in chronically hypokalemic dogs. *Anesth Analg* 62:991-994, 1983
6. Holliman CJ, Meuleman TR, Larsen KR, **Port JD**, Stanley TH, Pace NL, Warden GD: The effect of ketanserin, a specific serotonin antagonist on burn shock hemodynamic parameters in the porcine burn model. *J Trauma* 23:867-871, 1983
7. Wong KC, Tseng CK, Puerto BA, Puerto AX, Liu WS, **Port JD**: Chronic hypokalemia on epinephrine induced dysrhythmias during halothane, enflurane, or methoxyflurane with nitrous oxide anesthesia in dogs. *Anes Sinica* 21:139-146, 1983
8. Meuleman TR, **Port JD**, Stanley TH, Williard K, Kimball J: Immobilization of elk and moose with carfentanil. *J Wildl Manage* 48(1):258-262, 1984
9. Bailey PL, **Port JD**, Pace NL, Stanley TH, Kimball J: The ED₅₀ of carfentanil or elk immobilization with and without the tranquilizer R51703. *J Wildl Manage* 49(4):931-934, 1985

10. Stanley TH, **Port JD**, Letter to the editor: Fentanyl “Anesthesia” in dogs. *Anesthesiology* 62:837-838, 1985
11. Stanley TH, **Port JD**, Van der Maatin J, Kimball J: Treatment of stress hyperthermia in elk with ketanserin, a serotonin receptor blocker. *Vet Surg* 15(2):214-217, 1986
12. Bailey PL, **Port JD**, McJames SW, Reinersman L, Stanley TH: Is fentanyl an anesthetic in the dog? *Anesth Analg* 66:542-548, 1987
13. Clark NJ, **Port JD**, McJames SW, Stockham RJ, Stanley TH, Pace NL: Preservation of the ischemic canine myocardium: a comparison of hypothermia, lidoflazine, and ketanserin. *J Cardiothor Anes* 2(3):330-340, 1988
14. San Juan AC, **Port JD**, Wong KC: Hyperkalemia after dantrolene and verapamil-dantrolene administration in dogs. *Anes Analg* 67:759-762, 1988
15. Stanley TH, McJames SW, Kimball J, **Port JD**, Pace NL: Immobilization of elk with A-3080. *J Wildl Manage* 52:577-581, 1988
16. Bristow MR, Hershberger RE, **Port JD**, Minobe W, Rasmussen R: β_1 & β_2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. *Mol. Pharm.* 35:295-303, 1989
17. Bristow MR, **Port JD**, Hershberger RE, Gilbert EM, Feldman AM: The β -adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. *Europ Heart J* 10(Suppl B)45-54, 1989
18. Gilbert EM, **Port JD**, Hershberger RE, Bristow MR: Clinical significance of alterations in the β -adrenergic receptor-adenylate cyclase complex in heart failure. *Heart Failure* 5:91-98, 1989
19. Bristow MR, **Port JD**, Sandoval AB, Rasmussen R, Ginsburg R, Feldman AM: Beta-adrenergic receptor pathways in the failing human heart. *Heart Failure* 5:77-90, 1989
20. Bristow MR, **Port JD**, Gilbert EM: The role of receptor regulation in the treatment of heart failure. *Cardiovasc Drugs & Therapy* 3:971-978, 1990
21. **Port JD**, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Bristow MR: Neurotransmitter depletion compromises the ability of indirect acting amines to provide inotropic support in the failing human heart. *Circulation* 81:929-938, 1990
22. Bristow MR, Hershberger RE, **Port JD**, Sandoval A, Rasmussen R, Cates AE, Feldman AM: β -adrenergic pathways in nonfailing and failing human ventricular myocardium. *Circulation* 82(S1):I12-I25, 1990
23. Bristow MR, Anderson FL, **Port JD**, Skerl L, Hershberger RE, Larrabee P, O’Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM: Differences in β -adrenergic neuroeffector mechanisms in ischemic vs. idiopathic dilated cardiomyopathy. *Circulation* 84:1024-1039, 1991
24. Hayes JK, Smith KW, **Port JD**, Jordan WS: Comparison of tidal ventilation and high-frequency jet ventilation before and after cardiopulmonary bypass in dog using two-dimensional transesophageal echocardiography. *J Cardiothor Vasc Anes* 5:320-326, 1991
25. Hadcock JR, **Port JD**, Malbon CC: Cross-regulation between G-protein mediated pathways: activation of the inhibitory pathway of adenylyl cyclase increases the expression of β_2 -adrenergic receptors. *J Biol Chem* 266:11915-11922, 1991
26. Lee HR, Hershberger RE, **Port JD**, Rasmussen R, Renlund DG, O’Connell JB, Gilbert EM, Mealey PC, Volkman K, Menlove R, Bristow MR: Low-dose enoximone in subjects awaiting cardiac transplant: clinical results and effects on β -adrenergic receptors. *J Thorac Cardiovasc Surg* 102:246-258, 1991
27. Anderson FL, **Port JD**, Reid BB, Larrabee P, Hanson G, Bristow MR: Myocardial catecholamines and neuropeptide-Y depletion in the failing ventricles of patients with

- idiopathic dilated cardiomyopathy. Correlation with beta adrenergic receptor down-regulation. *Circulation* 85:46-53,1992
28. Anderson FL, **Port JD**, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR: Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. *J Cardiovasc Pharm* 20:800-806, 1992
 29. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, **Port JD** and Muller-Beckmann B: Receptor pharmacology of carvedilol in the human heart. *J Cardiovasc Pharmacol* 19(S1):S68-S80, 1992
 30. Hadcock JR, **Port JD**, Gelman MS and Malbon CC: Cross-talk between tyrosine kinase and G-protein-linked receptors: phosphorylation of β_2 -adrenergic receptors in response to insulin. *J Biol Chem* 267:26017-26022, 1992
 31. **Port JD**, Hadcock JR, and Malbon: Cross-regulation between G-protein-mediated pathways: acute activation of the inhibitory pathway of adenylylcyclase reduces β_2 -adrenergic receptor phosphorylation and increases β -adrenergic receptor responsiveness. *J Biol Chem* 267:8468-8472, 1992
 32. **Port JD**, Huang L-Y, and Malbon CC: β -adrenergic agonists that down-regulate receptor mRNA up-regulate a 35,000-Mr proteins(s) that selectively binds to β -adrenergic receptor mRNAs. *J Biol Chem* 267:24103-24108, 1992
 33. **Port JD**, Debellis C, Wiederin J, Peeters G, Barry WH, Bristow MR: Pharmacological characterization of cultured chick and frog myocardial β -adrenergic receptors. *J Pharmacol Exper Ther* 262:217-224, 1992
 34. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, **Port JD**: Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. *The Clinical Investigator (Klinische-Wochenschrift)* 70(S1):S105-S113,1992
 35. **Port JD**, and Malbon CC: Integration of transmembrane signaling: cross-talk among G-protein-linked receptors and other signal transduction pathways. *Trends Cardiovasc Med* 3:85-92, 1993
 36. Farrukh HM, White M, **Port JD**, Handwerger DA, Larrabee P, Klein J, Roden R, Skerl L, Renlund DG, Feldman AM, and Bristow MR: Up-regulation of β_2 -adrenergic receptors in previously transplanted, denervated nonfailing human hearts. *JACC* 22:1902-1908, 1993
 37. Bristow MR, Minobe WA, Raynolds MV, **Port JD**, Rasmussen R, Ray PE, and Feldman AM. Reduced β_1 -receptor mRNA abundance in the failing human heart. *J Clin Invest* 92:2737-2745, 1993
 38. White M, Roden RL, Skerl L, Larrabee P, Wollmering MM, **Port JD**, Minobe W, Anderson FA, Feldman AF and Bristow MR: Age-related changes in the β -adrenergic neuroeffector systems in the human heart. *Circulation* 90:1225-1238, 1994
 39. White M, Wiechmann RJ, Roden RL, Hagen MB, Wollmering MM, **Port JD**, Hammond E, Abraham WT, Wolfel EE, Lindenfeld JA, Fullerton D, Bristow MR. Cardiac β -adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: evidence for catecholamine-mediated myocardial damage. *Circulation* 92:2183-2189 1995
 40. Yoshikawa T, **Port JD**, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J* 16(Suppl B):8-16, 1996
 41. Pende A, Tremmel KD, DeMaria CT, Blaxall BC, Minobe W, Sherman JA, Bisognano J, Bristow MR, Brewer G, **Port JD**. Regulation of the mRNA binding protein, p37AUF1, by activation of the β -adrenergic receptor signal transduction pathway. *J Biol Chem* 271:8493-8501, 1996

42. Asano K, Dutcher DL, **Port JD**, Minobe WA, Tremmel KD, Roden RL, Bohlmeier TJ, Bush EW, Jenkin MJ, Abraham WT, Reynolds MV, Zisman, LS, Perryman MB, and Bristow MR. Selective down-regulation of the angiotensin II AT1 receptor subtype in failing human ventricle. *Circulation* 95:1193-1200, 1997
43. Bristow MR and **Port JD**. β -adrenergic blockade in chronic heart failure. *Scand Cardiovasc J (S47)*:45-55, 1998
44. Mitchusson KD, Blaxall BC, Pende A, and **Port JD**. Agonist-mediated destabilization of human β 1-adrenergic receptor mRNA; role of the 3' untranslated region. *Biochem Biophys Res Comm* 252:357-362, 1998
45. Pende A, Giacche M, Castigliola L, Contini L, Passerone, G, Patrone M, **Port JD**, and Lotti G. Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. *Biochem Biophys Res Comm* 266:609-614, 1999
46. Blaxall BC, Pellet A, Wu SC, Pende A, and **Port JD**. Purification and characterization of β -adrenergic receptor mRNA binding proteins. *J Biol Chem* 274:4290-4297, 2000
47. Bisognano JD, Weinberger, HD, Bohlmeier TJ, Pende A, Reynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Comunnal C, Singh K, Colucci W, Bristow MR, and **Port JD**. Myocardial-directed overexpression of the human β 1-adrenergic receptor in transgenic mice. *J Mol Cell Cardiol* 32:817-830, 2000
48. Gilbert EM, and **Port JD**. Deactivation of the sympathetic nervous system in patients with CHF: should we aim for full or partial beta adrenergic blockade? *Current Cardiology Reports* 2:225-232, 2000
49. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeier TJ, Brewer G, Malkinson AM, and **Port JD**. Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA-binding protein (AUF1) and Hu antigen R (HuR) in neoplastic lung tissue. *Molecular Carcinogenesis* 28:76-83, 2000
50. Asano K, Zisman, LS, Yoshikawa T, Headley V, Bristow MR and **Port JD**. Bucindolol, a nonselective β 1- and β 2-adrenergic antagonist, decreases β -adrenergic receptor density in embryonic chick ventricular myocyte membranes. *J Cardiovasc Pharm* 37:678-691, 2001
51. **Port JD**, and Bristow MR. Altered β -adrenergic receptor signaling in chronic heart failure. *J Mol Cell Cardiol* 33:887-905, 2001
52. **Port JD**, and Bristow MR. Perspective: β -adrenergic receptors, transgenic mice, and pharmacological model systems. *Mol Pharmacol* 60:629-631, 2001
53. Blaxall B, Pende A, Wu, S.C., and **Port JD**. Correlation between intrinsic mRNA stability and affinity of the mRNA binding proteins, AUF1(hnRNP D) and HuR, for A+U-rich mRNAs. *Mol Cell Biochem* 232:1-11, 2002
54. Communal C, Colucci WS, Remondino A, Sawyer DB, **Port JD**, Wichman SE, Bristow MR, and Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. *J Cardiac Failure* 8:86-92, 2002
55. Asano K, Bohlmeier TJ, Westcott JY, Zisman LS, Kinugawa K, Good M, Minobe WA, Roden RL, Wolfel EE, Lindenfeld J, **Port JD**, Perryman MB, Cleveland J, Lowes B, and Bristow MR. Altered expression of endothelial receptors in failing human left ventricles. *JMCC* 34:833-846, 2002
56. Headley V, Tanveer R, Greene S, Zweifach, and **Port JD**. Regulation of beta-adrenergic receptor mRNA stability by MAP kinase cascades. *Mol Cell Biochem* 258:109-119, 2004
57. Pino I, Zerbe LK, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, **Port JD**, Montuenga LM, and Malkinson AM. The relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth; implications of pre-mRNA processing. *Mol Carcinogenesis* 41:187-196, 2004

58. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, **Port, JD**, Lavori PW, and Bristow MR. A polymorphism within a conserved β 1-adrenergic receptor motif alters cardiac function and β -blocker response in human heart failure. *PNAS* 103:11288-11293, 2006
59. David P, Tanveer R, and **Port JD**. FRET-detectable interactions between the ARE binding proteins, HuR and p37AUF1. *RNA* 13:1453-1468, 2007
60. Vest RS, Davies KD, O'Leary H, **Port JD**, and Bayer KU. Dual mechanism of a natural CaMKII inhibitor blocks substrate but not T286 auto-phosphorylation. *Mol Biol Cell* 18:5024-5033, 2007
61. Pende A, Contini L, Sallo R, Passalacqua M, **Port JD**, and Lotti G. Characterization of RNA-binding proteins involved in the modulation of hAT1 receptor mRNA stability. *Cell Biochemistry and Function* 26:493-501, 2008
62. Sucharov K, Bristow MR, and Port JD. Regulation of miRNA expression in the failing human heart: functional correlates. *JMCC* 45:185-192, 2008
63. Tanveer R, Greene S, and **Port JD**. Regulation of AUF1 mRNA binding by MAPK phosphorylation. (submitted, in revision)
64. Gerecht PD, and **Port JD**. Intracellular localization of mRNA binding proteins. In preparation.

Abstracts:

1. Webster LR, Stanley TH, **Port JD**, Johansen R: Comparison of intravenous nitroglycerin and sodium nitroprusside on hypoxic pulmonary vasoconstriction. Presented at the annual meeting of the American Society of Anesthesiologists, 1978 Abstracts, pg. 67
2. Webster LR, Stanley TH, Razzeca K, **Port JD**: Comparison of cardiopulmonary bypass with membrane and bubble oxygenators on leukocyte phagocytosis during halothane anesthesia. Presented at the annual meeting of the American Society of Anesthesiologists, 1978 Abstracts, pg. 95
3. Sederberg J, Stanley TH, Reddy P, **Port JD**, Gillmor ST: Hemodynamic effects of butorphanol-oxygen anesthesia in dogs. *Anesthesiology* 53(3):S70, 1980
4. Kimball J, **Port JD**, Meuleman T, Williard K: Treatment of stress induced hyperthermia with a specific serotonin receptor blocker. Presented at the Janssen Research Foundation Workshop, 1981
5. Meuleman TR, **Port JD**, Hill D, Pace NL, Stanley TH: The cardiovascular and pulmonary effects of serotonin antagonism before and during endotoxic shock. Presented at the annual meeting of the International Anesthesia Research Society, 1982
6. Meuleman TR, Kimball J, **Port JD**, Stanley TH: Narcotic anesthesia without respiratory support following a single intramuscular injection. Presented at the annual meeting of the Southern Society of Anesthesiologists, 1982
7. Williard K, **Port JD**, Stanley TH, Andriano K: Cardiovascular effects of carfentanil during oxygen breathing in dogs. Presented at the annual meeting of Southern Society of Anesthesiologists, 1982
8. Meuleman TR, **Port JD**, Stanley TH, Pace NL: Effects of serotonin antagonism on endotoxic shock. Presented at the annual meeting of the Society of Critical Care Medicine, 1982
9. Jones RL, **Port JD**, Stanley TH: Protection of the ischemic myocardium during cardiopulmonary bypass: Ca^{++} blockers vs. hypothermia. Presented at the annual meeting of the Association of Cardiac Anesthesiologists, 1982

10. **Port JD**, Stanley TH, Steffey EP: Narcotic inhalation anesthesia. *Anesthesiology* 57:A344, 1982
11. Meuleman TR, Holliman CJ, **Port JD**, Larsen KR, Stanley TH, Williard K, Warden G: Serotonin blockade prevents post-burn pulmonary and systemic hypertension. *Anesthesiology* 57:A115, 1982
12. Meuleman TR, Williard K, **Port JD**, Stanley TH, Kimball J, Petty C: Immobilization of elk and moose with carfentanil. Presented at the annual meeting of the American College of Veterinary Anesthesiologists. 1982
13. Wong KC, **Port JD**, DeFriez C, Steffens JG: Cardiovascular responses to anoxic challenge in chronic hypokalemic dogs. Presented at the annual meeting of the International Anesthesia Research Society, 1983 Abstracts, pg. 76
14. Holliman CJ, Meuleman TR, **Port JD**, Larsen KR, Warden GD: Effects of ketanserin, a specific serotonin antagonist, on burn shock hemodynamic parameters in a porcine burn model. Presented at the annual meeting of the American Burn Association, 1983
15. **Port JD**, Stanley TH, McJames SW: Topical narcotic anesthesia *Anesthesiology* 59:A325, 1983
16. Williard K, **Port JD**, Stanley TH: Narcotic-oxygen anesthesia without respiratory support in the basally anesthetized dog. *Anesthesiology* 59:A321, 1983
17. **Port JD**, Jones RL, Stanley TH: Protection of the ischemic canine myocardium during cardiopulmonary bypass: Ca⁺⁺ blockers vs. hypothermia. *Anesthesiology* 59:A42, 1983
18. **Port JD**, Steffey EP, Stanley TH, Henrickson R: Carfentanil: the primate experience. Presented at the annual meeting of the American College of Veterinary Anesthesiologists, 1983 Abstracts, pg. 45
19. **Port JD**, Stanley TH, Steffey EP, Pace NL, Henrickson R, McJames SW: Intravenous carfentanil in the dog and rhesus monkey. *Anesthesiology*, 61:A378, 1984
20. Stanley TH, **Port JD**, Van der Maatin J, Kimball J: Treatment of malignant hyperpyrexia with a serotonin receptor blocker. *Anesthesiology* 61:A384, 1984
21. Stanley TH, **Port JD**, Kimball J, Oosterhuis JE: New drugs for immobilization of non-domestic hoofstock. Presented at the annual meeting of the American Association of Zoo Veterinarians, 1984 Abstracts, pg. 56
22. Dzelzkalns R, Bailey PL, **Port JD**, Pace NL, Stanley TH, Kimball J: Potentiation of opioid anesthesia without additional respiratory depression. Presented at the annual meeting of the Southern Society of Anesthesiologists, 1985
23. Soderberg JD, **Port JD**, Stockham RJ, Stanley TH: Protection of the ischemic canine myocardium. Presented at the annual meeting of the Western Society for Clinical Investigation, 1985
24. Clark NJ, **Port JD**, Ausems M, Stanley TH: Limited entero-systemic recirculation after gastric trapping of fentanyl in the dog. *Anesthesiology* 63:A375, 1985
25. San Juan AC, **Port JD**, Wong KC: Hyperkalemia after dantrolene in dogs. *Anesth and Anal* 65(2S):S131, 1986
26. **Port JD**, Sakashita C, Rollins DE: Immunoabsorption mediated extraction of fentanyl from biological specimens. *Fed Proc.* 46(3):400, 1987
27. **Port JD**, Bristow MR: Myocardial β_2 receptor subsensitivity in the failing heart. *JACC* 11(2):117A, 1988
28. **Port JD**, Bristow MR: Lack of spare β -adrenergic receptors in the human heart. *FASEB J* 2(4):A602, 1988
29. **Port JD**, DeBellis CC, Bristow MR: Pharmacologic characterization of cultured chick and frog myocardial β -adrenergic receptors. *Pharmacologist* A96, 1988

30. Hershberger RE, **Port JD**, Anderson FL: Somatostatin inhibits adenylate cyclase in human ventricular myocardium. *Circulation* 78(S2):560, 1988
31. **Port JD**, Hershberger RE, Gilbert EM, Bristow MR: β -adrenergic agonists in nonfailing, failing and transplanted human hearts *JACC* 13(2):143A, 1989
32. **Port JD**, DeBellis CC, Wiederin J, Peeters GA, Hershberger RE, Barry WH, Bristow MR: Long-term β -adrenergic receptor desensitization in cultured chick myocardial cells. *FASEB J* 3(4):A1044, 1989
33. **Port JD**, Larrabee P, Wiederin J, Durham D, Rasmussen R, Bristow MR: Differences in ventricular myocardial β -receptor expression in ischemic vs. idiopathic dilated cardiomyopathy. *Circulation* 80(S2):8, 1989
34. **Port JD**, Skerl L, O'Connell JB, Renlund D, Larrabee P, Bristow MR: Increased expression of β_2 -receptors in surgically denervated, previously transplanted human ventricular myocardium. *JACC* 15(2):84A, 1990
35. Wiechmann RJ, Eastburn T, Murray J, **Port JD**, O'Connell JB, Renlund DG, Hershberger RE, Bristow MR: Cardiac donor dysfunction: evidence for catecholamine-mediated myocardial injury. *JACC* 15(2):84A, 1990
36. Anderson FL, **Port JD**, Bristow MR, Hershberger RE, Kralios A, Hanson G: Neuropeptide Y in the failing human ventricle of patients with idiopathic dilated cardiomyopathy. *JACC* 15(2):30A, 1990
37. Wollmering MM, Wiechmann RJ, **Port JD**, Hershberger RE, Focaccio A, Bristow MR: Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. *JACC* 17(2):283A, 1991
38. Bristow MR, Durham C, Klien J, Rasmussen R, **Port JD**, Gesteland RR, Barry WH, Feldman AM: Down-regulation of β -adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. *Clin Research* 39:256A, 1991
39. White M, Wollmering M, Roden RL, **Port JD**, Minobe W, Skerl L, Handwerger DA, and Bristow MR: Decreased G protein functional activity, decreased agonist affinity and uncoupling of β -adrenergic receptors from mechanical response with aging in the human heart. *Circulation* 86(S1):I-766, 1991
40. Bristow MR, Handwerger DA, Klein J, and **Port JD**: Down-regulation of cardiac β_1 -adrenergic receptors by "atypical" β -blocking agents. *Circulation* 86(S1)I-646, 1992
41. White M, Wollmering M, Roden R, **Port JD**, Minobe W, Skerl L, Handwerger H, and Bristow MR: Age-related decrease in β -adrenergic responsiveness is not expressed in previously transplanted, denervated human heart. *Can J Cardiol* 8(Suppl B):96B, 1992
42. Bristow MR, Minobe W, **Port JD**, Ray PE, and Feldman AM: Decreased β_1 -adrenergic receptor mRNA levels correlate with decreased β_1 -receptor density in the failing human heart. *JACC* 21(2):100A, 1993
43. White M, Wollmering M, Roden RL, **Port JD**, Minobe W, Skerl L, Handwerger DA, and Bristow MR: Decreased G protein functional activity, decreased agonist affinity and uncoupling of β -adrenergic receptors from mechanical response with aging in the human heart. *Can J Cardiol* 8(Suppl B):131B, 1993
44. Bristow MR, Minobe WA, Reynolds MV, Roden RL, **Port JD**, and Feldman AM. Age-related decreases in β_1 -receptor mRNA abundance in human heart. *JACC* 23:17A, 1994
45. Lindenfeld J, White M, Roden RA, **Port JD**, and Bristow MR: Gender-related differences in age-associated down-regulation of human ventricular myocardial β -adrenergic receptors. *Clinical Research* 42:333A, 1994
46. Mitchusson K, Pende A, Minobe W, Blaxall B, Bristow MR, and **Port JD**. Up-regulation of AUF1, an mRNA binding protein, in failing human ventricular myocardium. *Cold Spring Harbor Symposium on Translational Control*, Abstracts: pg. 164, 1994

47. Lowes BD, Chidiac P, Olsen S, **Port JD**, Bouvier M, Gilbert EM, and Bristow MR. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β adrenergic receptor blocking agents. *Circulation* 90(4):I-543, 1994
48. Asano K, Minobe W, Mitchusson KD, Dutcher D, Roden R, **Port JD**, & Bristow MR. Selective down-regulation of angiotensinogen II AT1 receptors in failing human heart: relationship to β 1-receptor down-regulation. *JACC (Feb)*:291A, 1995
49. **Port JD**, Mitchusson KD, Pende A, Minobe M, Brewer G, Bristow MR. Regulation of p37AUF1, an mRNA binding protein, in human ventricular myocardium. *FASEB J* 9(6):A1277, 1995
50. Blaxall B, Mitchusson KD, Pende A, Brewer G, **Port JD**. β -adrenergic receptor mediated regulation of p37AUF1, an mRNA binding protein, in DDT1-MF2 cells. *FASEB J* 9(6):A1277, 1995
51. Pickrell JW, Abraham WT, **Port JD**, Roden RL, Bristow MR, Hammond EH. Evidence for decreased adrenergic nerve density in the failing human heart. *Circulation* 92:I-191, 1995
52. Mitchusson KD, Roden RL, Abraham WT, Bristow MR, **Port JD**. Regulation of the norepinephrine transporter by its endogenous ligand. *Circulation* 92:I-568, 1995
53. Roden RL, Minobe W, Dutcher DL, Tremmel KD, **Port JD**, Bristow MR. Differential regulation of β 1- and β 2-adrenergic receptors and mRNA by nonselective β -agonist exposure in preparation of isolated human heart. *JACC* 27(Suppl A):288A, 1996
54. Pende A, DeMaria CT, Sherman J, Tremmel KD, Brewer G, **Port JD**. Binding of p37AUF1, an mRNA destabilizing protein, to human β 1-adrenergic receptor mRNA. *Keystone Symposia: Molecular Biology of the Cardiovascular System*, pg. 47, 1996
55. Tremmel KD, Pende A, Bristow MR, **Port JD**. Regulation of human β 1-adrenergic receptor mRNA stability by agonist exposure. *Keystone Symposia: Molecular Biology of the Cardiovascular System*, pg. 47, 1996
56. Tremmel KD, and **Port JD**. Regulation of human beta1-adrenergic receptor mRNA stability. *American Heart Association Scientific Conference on the Molecular Biology of the Normal, Hypertrophied, and Failing Heart*, abstract #60, 1996
57. Bristow MR, Abraham WT, Gilbert EM, Yoshikawa T, and **Port JD**. Relationships between carvedilol stereoisomer plasma concentrations and β -receptor occupancies in subjects with chronic heart failure in the MOCHA trial. *European Heart J* 17(Suppl):135, 1996
58. Tremmel KD, and **Port JD**. Regulation of beta1-adrenergic receptor mRNA stability: critical role of the 3' untranslated region. *Mol Biol Cell* 7:300a, 1996
59. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. *Mol Biol Cell* 7:300a, 1996
60. Lowes BD, Abraham WT, Dutcher DL, Roden RL, Crisman TS, Minobe W, **Port JD**, Larrabee P, Gilbert EM, and Bristow MR. Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled trial. *Circulation* 94:I-664, 1996
61. Tremmel KD, and **Port JD**. Regulation of beta1-adrenergic receptor mRNA stability: role of the 3' untranslated region. *Circulation* 94:I-288-9, 1996
62. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. *Circulation* 94:I-407, 1996
63. Blaxall BC, Pende A, Brewer G, and **Port JD**. Differential affinities of the mRNA binding protein, AUF1, for beta-adrenergic receptor mRNAs. *Cold Spring Harbor Symposium on Translational Control. Abstracts*, pg. 37, 1996
64. Tremmel KD and **Port JD**. Regulation of human beta1-adrenergic receptor mRNA stability: critical role of the 3'UTR. *Cold Spring Harbor Symposium on Translational Control. Abstracts*, pg. 271, 1996

65. Lowes BD, Minobe WA, Abraham WT, Roden RL, **Port JD**, Gilbert EM, Larrabee P, and Bristow MR. Downregulation of α - and upregulation of β -myosin heavy chain in intact, failing human ventricles. *JACC* 25(Suppl A):422A-423A, 1997
66. Bisognano JD, Pende A, Tremmel KD, Dutcher DL, Knudson OA, Bohlmeyer TJ, Bristow MR, and **JD Port**. Preliminary characterization of a transgenic mouse overexpressing the human β 1-adrenergic receptor. *J Invest Med* 45:210A, 1997
67. Tremmel KD, Pende A, Blaxall B, and **Port JD**. The 3' untranslated region of the human beta1-adrenergic receptor is necessary but not sufficient for agonist-mediated destabilization. *Circulation* 96:I-52, 1997
68. Vickstrom KL, Weinberger HD, Hoover E, **Port JD**, Knudsen OA, Valdes-Cruz L, Bristow MR, and Leinwand LA. Hypertrophy- and dilation-associated genes in murine cardiomyopathy. *Circulation* 96:I-570, 1997
69. **Port JD**, Weinberger HD, Bisognano JD, Knudson OA, Bohlmeyer TJ, Pende A, and Bristow MR. Echocardiographic and histopathological characterization of young and old transgenic mice overexpressing the human β 1-adrenergic receptor. *JACC* 31(Suppl A):177A, 1998
70. Wichman SE, Minobe WA, Roden RL, **Port JD**, Asano K, Bristow MR. Differential regulation of β 1- and β 2-adrenergic receptor proteins, and β 1-adrenergic receptor protein and mRNA expression in response to β -agonist exposure in isolated human heart preparations. *Circulation* 98(17):I-491, 1998
71. Blaxall BC, Keil KH, Bohlmeyer TJ, Bristow MR, Brewer G, Malkinson AM, and **Port JD**. Association of the mRNA binding protein AUF1 with growth phenotype. Cold Spring Harbor Symposium on Translational Control, Abstracts: pg. 46, 1998
72. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeyer TJ, Brewer G, Malkinson AM, and **Port JD**. Elevated expression of the mRNA binding protein AUF1 in mouse lung tumors. *Proc Am Assoc Cancer Res* 40:438, 1999
73. Blaxall BC, Dwyer-Nield LD, Keil KH, Bauer AK, Bohlmeyer TJ, Brewer G, Malkinson AM, and **Port JD**. Expression of the mRNA binding protein AUF1 correlates with growth. *FASEB J* 13(4 Part I):A356, 1999
74. Pende A, Giacche M, Castigliola L, Contini L, Patrone M, **Port JD**, and Lotti G. Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. *J Hypertension* 17:S141, 1999
75. Blaxall B, Pende A, Wu, S.C., and **Port JD**. Correlation between mRNA stability and affinity of the mRNA binding proteins AUF1 and HuR for A+U-rich mRNAs. AHA Scientific Conference on the Molecular, Cellular, and Integrated Physiological Approaches to the Failing Heart. Abstracts, #94, 1999
76. Communal C, Colucci WS, Sawyer DB, **Port JD**, Wichman SE, Bristow MR, and Singh K. Differential modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases in failing human myocardium. *Circulation* 100:I-199, 1999
77. Pende A, Contini L, Gilberti C, Giacche M, **Port JD**, and Lotti G. Characterization of the binding of cytosolic RNA-binding proteins to the human AT1 receptor mRNA: any role for the A1166C polymorphism? *J Hypertension* 18(Suppl 2):S75, 2000
78. Perryman MB, **Port JD**, Roden RR, Sederberg JH, and Bristow MR. A comparison of gene expression in failing and non failing human left ventricular tissue. *Circulation* 102:II-449-450, 2000
79. Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ, Malkinson AM, and **Port JD**. Expression and localization of AUF1/hnRNP D and HuR in hyperplastic and neoplastic lung tissues. Cold Spring Harbor Symposium on Translational Control, pg. 51, 2000

80. **Port JD**, Headley V and Tanveer R. Regulation of beta-adrenergic mRNA stability by kinase cascades. 4th West Coast Meeting on mRNA Stability and Translation, Seattle, WA. Scientific Program and Abstracts, pg.36, 2001
81. Contini L, Sallo R, Patrone M, **Port JD**, A. Pende A Lotti G. Caratterizzazione in fibrocellule muscolari lisce vascolari umane di proteine leganti l'mRNA dei recettori AT1 ed AT2. Annual Meeting, Societa Italiana dell'Ipertensione Arteriosa, Roma, IT 2001.
82. Pino I, Cospes, P, Pío R, Dwyer-Nield L, Meyer AM, **Port D**, Montuenga L, and Malkinson AM. Enhanced expression of proteins that regulate alternative splicing of pre-mRNA in mouse lung tumors. Proceedings of the American Association of Cancer Research, abstract #842, 2002
83. Lowes BD, Minobe WA Hunter L, Leach S, **Port JD**, Linseman JV, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: characterization of a human model of molecular discovery. J Cardiac Failure 8:S13, 2002
84. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, **Port JD**, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered gene expression with improvement in dilated cardiomyopathy. J Cardiac Failure 8:S35, 2002
85. Headley V, Tanveer R, Greene S, and **Port JD**. Regulation of beta-adrenergic receptor mRNA stability by MAP kinase cascades. Cold Spring Harbor Symposium on Translational Control, pg. 142, 2002
86. Tanveer R, Headley V, Greene S, Cao H, Blackshear PJ, Perryman MB, Fox J, and **Port JD**. Novel proteins that bind to A+U-rich elements of beta-adrenergic receptor mRNAs. Cold Spring Harbor Symposium on Translational Control, pg 335, 2002
87. Zerbe L, Peebles K., Pino I, Blaxall B, D. **Port JD**, L. Montuenga L, and Malkinson A. Expression of several pre-mRNA processing proteins increase during pulmonary growth. Mol Biol Cell 13:abstract #602, 2002
88. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, **Port JD**, Perryman MB, and Bristow MR. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered gene expression with improvement in dilated cardiomyopathy. Circulation 106:II-384, 2002
89. Zerbe L, Pino I, **Port JD**, Montuenga L, and Malkinson A. Increased ASF/SF2 and hnRNP A1 expression in early mouse lung tumorigenesis. Keystone Meeting on RNA Trafficking, Transport and Processing, 2003
90. **Port JD**, Headley V, Tanveer R, Zweifach A, and Greene S. Regulation of beta-adrenergic receptor mRNA stability by MAP kinase cascades. RNA Society Meeting, 2003
91. **Port JD**, Headley V, Tanveer R, Zweifach A, and Greene S. Signaling pathways and AUBPs in the regulation of G-protein-coupled receptor gene expression. First International Meeting on ARE's and AUBP's in mRNA Stability and Translational Control, 2003
92. Chesoni SA, Wilson G, Patel R, Tempesta C, Welsh J, **Port JD**, Maldowney R and Brewer G. Genome-scale identification and cloning of human cardiac mRNA associating with AUF1. Cold Spring Harbor Symposium on Translational Control, 2004
93. Malkinson A, Mason R, Stearman R, Geraci M, **Port JD**, Luis Montuegna L, and Zerbe L. Molecular biotechnologies that detect blood-borne protein biomarkers at early stages of lung cancer in a highly translatable mouse model. Butcher Symposium, UCHSC, 2004
94. **Port, JD**, Green S, and Tanveer R. G-protein coupled receptor mRNA stability: factors and signaling pathways. EMBO Workshop on mechanisms and regulation of mRNA turnover. Arolla, Switzerland, 2005

95. David PS, Tanveer R, **Port JD**. FRET-based detection of HuR-AUF1 interaction. RNA Society Annual Meeting, 2006
96. Lowes BD, Gottlieb S, Robertson, O'Connor C, **Port JD**, Liggett S, Bristow MR. Differential Effects of beta-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy. Annual meeting, HFSA, 2006
97. Lowes BD, Gottlieb S, Robertson, O'Connor C, **Port JD**, Thaneemit-Chen S, Liggett S, Bristow MR. Differential Effects of beta-1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy. *Circulation* 114:II-443, 2006
98. Nelson B, Morrison J, Nelson P, **Port JD**, Robertson AD, Bristow MR. Beta-blocking agents have codon 389 Arg/Gly genotype specific effects in isolated human heart preparations. *JACC*, 2006
99. David P, Tanveer R, **Port JD**. Cellular localization of HuR and AUF1. Stress granules or P-bodies? RNA Society Annual Meeting, 2007
100. Bristow MR, and **Port JD**. Improvement in heart failure therapy by genetic targeting. Cold Spring Harbor conference on Pharmacogenomics, Hinxton UK, 2007
101. Sucharov K, Bristow MR, **Port JD**. Regulation and function of MicroRNAs in the failing human heart. Keystone Conference on Pathological and Physiological Regulation of Cardiac Hypertrophy, 2008
102. Walsh R, Farmer R, Kelly M, Nelson P, Morrison J, **Port JD** and Bristow MR. Human myocardial beta₁ 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. HFSA, 2008
103. Kline K, Minobe W, Lowes B; **Port JD**, Bristow MR, and Wu C. Targeted proteomic analysis of the beta-adrenergic receptor signaling pathway in human cardiac biopsies collected over the course of beta-blocker treatment. *Am Soc Mass Spec*, 2008
104. Mason RP, Kubant R, Jacob RF, Jacoby AM, **Port JD**, Bristow MR, and Malinski T. Effects of bucindolol and its enantiomers on nitric oxide and peroxynitrite release from white, african american and mexican american endothelial cells. HFSA, 2008
105. Mason RP, Kubant R, Jacob RF, Jacoby AM, **Port JD**, Bristow MR, and Malinski T. Effect of the beta₃-receptor antagonist SR59230A on bucindolol-induced release of nitric oxide and peroxynitrite from human endothelium. HFSA, 2008
106. Lindenfeld J, Liggett SB, Plehn J, **Port JD**, Fiuzat M, Budhathoki CB, and Bristow MR. Ischemic cardiomyopathy response to bucindolol may be differentially influenced by beta₁ 389 Arg/Gly and alpha_{2c} genotypes. HFSA, 2008
107. Lindenfeld J, Plehn JF, Liggett SB, **Port JD**, Fiuzat M, Robertson AD, Budhathoki CB, Bristow MR. Different patterns of LVEF/remodeling and clinical endpoint effects for bucindolol in beta₁-AR 389 Arg/Gly genotypes. HFSA, 2008
108. Walsh R, Farmer R, Kelly M, Nelson P, Morrison J, **Port JD**, and Bristow MR. Human myocardial beta₁ 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. HFSA, 2008
109. Sucharov C, Lowes B, Bristow MR, and **Port JD**. miRNA expression profile in patients treated with beta-blocker therapy. AHA Cardiovascular Basic Sciences Conference 2008. Heart failure: molecular mechanisms and therapeutic targets. 2008
110. Sucharov C, Bristow MR, and **Port JD**. Differential expression of miRNAs in failing versus nonfailing human heart: functional correlates with gene expression programs. FASEB Summer Conference, 2008

111. Sucharov C, Bristow MR, and **Port JD**. Role of miRNAs in heart failure: are the causal and are they potential therapeutic targets. RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, 2008
112. Bristow MR, Liggett SB, and **Port JD**. Adrenergic receptor polymorphisms and response to bucindolol in heart failure. Cold Spring Harbor Labs Pharmacogenomics Meeting, 2008

Invited Speaker:

1. Department of Defense, Aberdeen Proving Grounds, MD. Visiting Scientist. 1984
2. Division of Cardiology, University of Colorado HSC. (research seminars and/or Cardiology grand rounds) 1991, 92, 93, 94, 95, 96, 06
3. Program in Hormones and Cancer, University of Colorado HSC. 1992.
4. Italian Society of Cardiology, Brescia, Italy. October, Invited Speaker. 1995
5. Department of Pharmacology, University of Colorado HSC, Annual Research Retreat. Invited Speaker. 1995
6. Frontiers of Cardiology, Baylor College of Medicine & Kelsey-Seybold Foundation. Winter Park, CO. Invited Speaker. 1996
7. Wyeth-Ayerst Research, Princeton, N.J., Visiting Scientist. 1996
8. Program in Hormones and Cancer, University of Colorado HSC. 1996
9. Nexstar Corp., Boulder CO. Invited Speaker. 1997
10. Bristol-Myers, Squibb Pharmaceutical Research Institute, Wallingford CT., Visiting Scientist. 1997
11. Gordon Conference on Catecholamines, Proctor Academy. Invited Speaker. 1997
12. Division of Cardiology, University of Cincinnati, Visiting Professor. 1997
13. Department of Pharmacology, University of Tennessee at Memphis, Visiting Professor. 1998
14. Department of Pharmacology and Toxicology, University of Utah, Visiting Professor. 1998
15. RNA Club, University of Colorado at Boulder. Invited Speaker. 1998
16. Division of Molecular Cardiology, Albert Einstein College of Medicine, Visiting Professor. 1998
17. Institute for Cellular and Molecular Biology, University of Texas at Austin, Visiting Professor. 1998
18. Cardiovascular Biology Group, Boston University, Visiting Professor. 2000
19. Gill Heart Institute, University of Kentucky, Visiting Professor. 2000
20. Mario Negri Institute for Pharmacological Research, Bergamo Italy, Visiting Professor. 2001
21. Department of Internal Medicine, University of Genoa, Italy, Visiting Professor. 2001
22. Symposium on "Catecholamines in Heart Disease", Medical University of Luebeck, Germany. Invited Speaker. 2001
23. Departments of Biochemistry and Internal Medicine, University of Genoa, Italy, Visiting Professor. 2002
24. Department of Experimental Pathology and Oncology, University of Florence, Italy, Visiting Professor, 2002
25. University of Wyoming, Invited speaker to NIH sponsored symposium on "Possibilities and Pitfalls of Mining DNA Micro-Array Data: From Mice to Men". 2003
26. Department of Cell Biology and Physiology, University of New Mexico, Visiting Professor, 2003
27. First International Meeting on ARE and AUBPs in Translational Control, Florence, Italy, Invited Speaker, Meeting Advisory Board, and Organizing Committee, 2003

28. Annual Meeting of the American Heart Association, Invited Speaker, Symposium on Post-transcriptional mechanisms of gene expression and their role in hypertrophy, 2003
29. Cardiovascular Research Institute, University of South Dakota, Invited Speaker, 2005
30. Department of Pharmacology, University of Wisconsin at Madison, Visiting Professor, 2005
31. EMBO Workshop: Regulation of mRNA Turnover, Arolla, Switzerland, Invited Speaker, 2005
32. Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Visiting Professor, 2005
33. Institute for International Research, Invited speaker, Incorporating Pharmacogenomics in Clinical Studies, Baltimore MD, 2006
34. ASPET/Experimental Biology, Invited speaker, Symposium Chair: Symposium on Post-transcriptional regulation of gene expression, 2007
35. XIX World Congress of the International Society of Heart Research, Bologna, Italy, Invited Speaker, 2007
36. Istituto Nazionale Ricerca sul Cancro (IST), Genoa, Italy, Visiting Professor, 2007
37. Central Labs Partnering, Invited Speaker, 2008
38. CHI's Molecular Medicine Tri-Conference, Invited Speaker, 2008
39. CHI's Genotype and Association Studies conference, San Francisco, CA Invited speaker, 2008
40. FASEB Summer Meeting, Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay, Il Ciocco, Italy, Oral presentation, 2008
41. RNA Turnover 2008: RNA Regulatory Mechanisms Implicated in Human Diseases Both Rare and Common, Asheville, NC, Meeting Organizer, Invited Speaker, 2008
42. Cold Spring Harbor Laboratories, Pharmacogenomics meeting, Cold Spring Harbor, NY, Oral presentation, 2008
43. NIH, Institute on Aging, Invited speaker, 2009
44. ASPET/Experimental Biology, Invited speaker, Symposium Chair: MicroRNAs as biological effectors and as pharmacological targets in the cardiovascular system, 2009